Skip to main content
. 2023 May 30;19(1):2211896. doi: 10.1080/21645515.2023.2211896

Table 6.

Non-inferiority immunogenicity in susceptible subjects.

group 5-dose PVRV-WIBP vs 5-dose PVRV-LNCD p-value 4-dose PVRV-WIBP vs 5-dose PVRV-LNCD p-value
GMT ratio (95%) 0:14:42/35 1.21 (1.06,1.37) .0011 1.03 (0.91,1.17) .5452
GMT ratio (95%) 14 day PWVa 1.31 (1.17,1.46) <.0001 1.08 (0.98,1.19) .0892
Seroconversion rate difference (95%) 0.00 (−1.47,1.45) 1.0000 0.00 (−1.38,1.45) 1.0000

a14-day PWV, 14 days after the whole vaccine schedule. GMT,geometric mean titer.